A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy
Evan Gross, Mingjia Li, Ming Yin, Delaney Orcutt, Duncan Hussey, Elliot Trott, Sarah K. Holt, Erin R. Dwyer, Joel H. Kramer, Kaylee Oliva, John L. Gore, George R. Schade, Daniel W. Lin, Scott S. Tykodi, Evan Hall, John A. Thompson, Anish B. Parikh, Yuanquan Yang, Katharine A. Collier, Abdul Miah, Sherry Mori-Vogt, Megan Hinkley, Amir Mortazavi, Paul Monk, Edmund Folefac, Steven K. Clinton, Sarah P. Psutka
Topics & Concepts
MedicineRenal cell carcinomaInternal medicineSystemic therapyRetrospective cohort studyProportional hazards modelClinical endpointOncologyKidney cancerCohortCancerNephrectomySurgeryUrologyClinical trialKidneyBreast cancerRenal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers